Amgen Inc
Market cap $203.0B
$376.04
AMGN
$376.04
+1.22% today
Buy with €1M virtual cash · No real money
Amgen Inc (AMGN) is a publicly traded company listed on the XNAS. As of July 27, 2026, Invest's signal rates AMGN a Hold, with the stock up 22% over the past year. You can practice trading AMGN risk-free with €1,000,000 in virtual cash.
Key stats
As of July 27, 2026
Market Cap
$203.0B
Volume
2.5M
52-wk High
$391.29
52-wk Low
$269.77
Day High
$379.41
Day Low
$372.16
P/E (TTM)
26.15
Revenue (TTM)
$37.2B
EPS (TTM)
$14.38
Performance
1M
+7.0%
6M
+8.3%
1Y
+21.6%
Invest signal · AMGN
HoldAlgorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.
AMGN overview
AI overviewRevenue & EPS — last 8 quarters
QoQ rev -12.6%Revenue
$9BEPS (diluted)
$3.34 per shareLatest AMGN news
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?
The Motley Fool · 3d ago
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight
GlobeNewswire Inc. · 3d ago
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight
GlobeNewswire Inc. · 5d ago
Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?
The Motley Fool · 6d ago
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes
GlobeNewswire Inc. · Jul 17
About Amgen Inc
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019).
The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza.
Amgen also has a growing biosimilar portfolio.
Employees
31,500
30-Day Win Rate · AMGN
13 days
10 days
Last 23 sessions
How to practice trading AMGN
- 1
Use the AMGN buy panel above
Set a quantity and hit Buy at the real market price — right here, nothing to download.
- 2
Trade with €1,000,000 virtual cash
You get a million in virtual money instantly to invest, risk-free.
- 3
Create a free account to save it
Sign up in seconds to keep your portfolio and track its performance.
- 4
Track and compete
Watch your portfolio grow and climb the global leaderboard — or start a private league.
- 5
Prefer mobile? Get the iOS app
Invest is also free on the App Store, synced with your web account.
Top AMGN traders on Invest
Full leaderboardFrequently asked questions
Is AMGN a good stock to buy right now?
As of July 27, 2026, Invest's signal rates AMGN a Hold, based on its price trend, valuation, and fundamentals (P/E around 26.2), with the stock up 22% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading AMGN risk-free first.
What is Amgen Inc's (AMGN) market cap?
Amgen Inc has a market capitalization of approximately $203.0B, on trailing-twelve-month revenue of about $37.2B.
How has AMGN stock performed?
AMGN is up 22% over the past year and up 8% over six months. Its 52-week range runs roughly from $269.77 to $391.29. Past performance doesn't predict future results.
How can I practice trading AMGN for free?
On Invest you get €1,000,000 in virtual cash and can buy AMGN at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.
More stocks to practice
Designs the iPhone, Mac, and a huge services ecosystem.
Windows, Office, Azure cloud, and enterprise software.
The leading designer of AI and gaming GPUs.
E-commerce giant and the largest cloud provider (AWS).
Google Search, YouTube, Android, and cloud.
Facebook, Instagram, WhatsApp, and the metaverse.
Compare AMGN with peers